Simplified Switching to Once‐Weekly Insulin Icodec Without an Initial One‐Time Additional Dose Versus Once‐Daily Insulin Glargine U100 in Basal Insulin‐Treated Type 2 Diabetes ( ONWARDS 10): A Randomised Controlled Trial
Primary result · Change in HbA1cResult — go to the resultEstimated treatment difference −0.2 %-points 95% CI −0.4 to −0.1Authors' conclusion
Omitting the one-time additional dose simplifies switching to icodec in adults with basal-insulin-treated T2D without compromising initial glycaemic control.
Study context
- Population
- Adults with basal-insulin-treated T2D with HbA1c 7.0%-10.0%
- Participants
- 412 adults
- Comparison
- Once-weekly icodec without initial one-time additional dose vs once-daily insulin glargine U100
- Icodecn = 206
- Glargine U100n = 206reference
- Primary endpoint
- Change in HbA1c from baseline (non-inferiority margin: 0.3%-points)
- Follow-up
- Week 26
Methodological detailstreat-to-target, open-label, phase 3b, non-inferiority
- Treat-to-target
- Open-label
- Phase 3b
- Non-inferiority
Primary result
Change in HbA1c
Estimated treatment difference
−0.2 %-points
95% CI −0.4 to −0.1
P < 0.0001
Change by group
Icodec
7.2
estimated mean · %
Glargine U100
7.5
estimated mean · %
Icodecvs Glargine U100
estimated treatment difference −0.2 %-points (95% CI −0.4 to −0.1); P < 0.0001
As reported in the abstract
Secondary outcomes
Estimated mean change, %-points
| Outcome | Icodec | Glargine U100 | Estimated treatment difference (%-points) (95% CI) | P value | |
|---|---|---|---|---|---|
| Change in TIR (70-180 mg/dL [3.9-10.0 mmol/L]) · baseline (weeks −4 to 0) to weeks 22-26 | 18.0 | 12.1 | 5.9 (2.6–9.2) | P = 0.0005 | |
| −50510Difference, %-points (linear scale) |
Self-measured blood glucose after icodec initiation
- Self-measured blood glucose did not increase following icodec initiation
Safety
Combined clinically significant or severe hypoglycaemia · weeks 0-31
Combined clinically significant or severe hypoglycaemia · weeks 0-31
- Rate numerically lower with icodec than with glargine U100
Original publication
Simplified Switching to Once‐Weekly Insulin Icodec Without an Initial One‐Time Additional Dose Versus Once‐Daily Insulin Glargine U100 in Basal Insulin‐Treated Type 2 Diabetes ( ONWARDS 10): A Randomised Controlled Trial. Diabetes Obes Metab. Published 21 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →